Randomization of Single vs Multiple Arterial Grafts (ROMA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03217006|
Recruitment Status : Recruiting
First Posted : July 13, 2017
Last Update Posted : April 20, 2022
The primary hypothesis of ROMA is that in patients undergoing primary isolated non-emergent coronary artery bypass surgery (CABG), the use of two or more arterial grafts compared to a single arterial graft is associated with a reduction in the composite outcome of death from any cause, any stroke, post discharge myocardial infarction and/or repeat revascularization. The secondary hypothesis is that in patients undergoing primary isolated non-emergent CABG, the use of two or more arterial grafts compared to a single arterial graft is associated with improved survival.
Prospective event-driven unblinded randomized multicenter trial of at least 4,300 subjects enrolled in at least 25 international centers. Patients will be randomized to a single arterial graft (SAG) or multiple arterial grafts (MAG). Patients will be randomized in a 1:1 fashion between the two groups. Permuted block randomization with random blocks stratified by the center and the type of second arterial graft will be used to provide treatment distribution in equal proportion.
|Condition or disease||Intervention/treatment||Phase|
|Coronary Artery Disease Heart Diseases||Procedure: Single arterial graft Procedure: Multiple arterial grafting||Not Applicable|
In the 1980's, it was recognized that long-term survival was enhanced in patients undergoing coronary surgery when the left anterior descending (LAD) was grafted with a left internal thoracic artery (ITA) rather than a saphenous vein (1). This difference was predicated, at least in part, due to greater and more durable patency of the left ITA compared to an increased early occlusion rate and later progressive atherosclerosis of saphenous vein grafts (SVG) (2).
For more than 20 years it has generally been accepted that patients who receive multiple arterial grafts (AGs) at the time of coronary artery bypass surgery (CABG) have increased postoperative survival compared to those who receive only one AG, especially over the long term (3-5). The current United States and European Guidelines encourage the use of AGs in patients with a long life expectancy (6, 7). Last year, a position paper from the Society of Thoracic Surgeons strongly recommended a wider use of AGs (8).
The putative mechanism underlying the AG hypothesis is greater patency. In line with the original findings of improved LAD graft patency with ITA vs. SVG, data from randomized control trials (RCTs) as well as observational studies and a network meta-analysis (9) have demonstrated that the patency of the RA, as well as the right ITA, exceed that of a SVG, providing mechanistic basis to support the AG hypothesis.
ROMA is a two arm event driven randomized multi-centre trial aimed at evaluating the impact of the use of one ITA vs two or more AGs for CABG on a composite of death from any cause, any stroke, post discharge myocardial infarction and/or repeat revascularization. The trial is powered to detect a 20% relative reduction in the primary outcome with 90% power at 5% alpha.
The primary aim is to conduct a multicenter international randomized control trial to test the hypothesis that the use of a two or more AGs compared to a single arterial graft is associated with a reduction in the composite outcome of death from any cause, any stroke, post discharge myocardial infarction and/or repeat revascularization.
The secondary aim is to conduct a multicenter international randomized control trial to test the hypothesis that the use of two or more AGs compared to a single arterial graft is associated with improved survival.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||4300 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Patients undergoing coronary artery bypass surgery will be in one of two groups. One group will receive a single arterial graft and the second group will receive two or more arterial grafts.|
|Masking:||Single (Outcomes Assessor)|
|Masking Description:||The endpoint assessors will be blinded to treatment allocation (PROBE).|
|Official Title:||Randomized Comparison of the Clinical Outcome of Single Versus Multiple Arterial Grafts: the ROMA Trial|
|Actual Study Start Date :||January 7, 2018|
|Estimated Primary Completion Date :||June 30, 2027|
|Estimated Study Completion Date :||January 1, 2030|
Experimental: Single Arterial Group
Patients in this group will receive a single arterial graft which will be the left internal thoracic artery. Additional grafts used in this group will all be venous grafts.
Procedure: Single arterial graft
This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
Experimental: Multiple Arterial Group
Patients in the group will receive multiple arterial grafts. All patients will receive at least two arterial grafts, the left internal thoracic artery with the addition of either the right internal thoracic artery or the radial artery as the second conduit. Some patients may receive additional arterial grafts consisting of the radial artery, the right internal thoracic artery, or the right gastroepiploic artery.
Procedure: Multiple arterial grafting
This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
- Composite Outcome [ Time Frame: > 72 hours after surgery and/or repeat revascularization ]A composite of death from any cause, any stroke, post discharge myocardial infarction and/or repeat revascularization.
- 30-day mortality [ Time Frame: 30 days post-operatively ]Death from any cause at 30-days
- Major postoperative complications [ Time Frame: In-hospital stay, up to 30 days post-operatively ]Revision for bleeding, perioperative myocardial infarction, any stroke, need for dialysis, need for tracheostomy, and surgical site infection.
- Sternal wound complication [ Time Frame: 6 months post-operatively ]Wound drainage, skin separation, unstable sternum, and sternal dehiscence, infection
- Composite Outcome of Death from any cause [ Time Frame: Analysis will be performed after 631 events. The investigators assume this will occur at a mean follow-up of 5 years. ]A composite of death from any cause, post discharge myocardial infarction,stroke, and/or repeat revascularization
- Stroke [ Time Frame: Analysis will be performed after 631 events. The investigators assume this will occur at a mean follow-up of 5 years. ]Post discharge myocardial infarction and repeat revascularization considered as individual events
- Cause-specific death (cardiac vs non-cardiac) [ Time Frame: Analysis will be performed after 631 events. The investigators assume this will occur at a mean follow-up of 5 years ]Death as either cardiac or non-cardiac in etiology
- Hospital readmissions [ Time Frame: Analysis will be performed after 631 events. The investigators assume this will occur at a mean follow-up of 5 years ]Hospital readmissions with specific causes
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03217006
|Contact: Mario Gaudino, MDfirstname.lastname@example.org|
|Contact: Marshagay Rodriques||(212) email@example.com|
|Principal Investigator:||Mario Gaudino, MD||Weill Medical College of Cornell University|
|Principal Investigator:||Stephen Fremes, MD||Sunnybrook Health Sciences Centre|